Journal Mobile Options
Table of Contents
Vol. 220, No. 3, 2010
Issue release date: April 2010
Dermatology 2010;220:254–258

Dowling-Degos Disease: Case Report and Review of the Literature

Batycka-Baran A. · Baran W. · Hryncewicz-Gwozdz A. · Burgdorf W.
aDepartment of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland; bDepartment of Dermatology, Ludwig Maximilian University, Munich, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Dowling-Degos disease (DDD) is an unusual pigmentary disorder usually caused by mutations in keratin 5. A 44-year-old woman in good general health presented due to the recent appearance of numerous pigmented macules on her axillary and anogenital skin. A biopsy showed lacy, finger-like epidermal extensions into the dermis which were heavily pigmented and associated with tiny cysts or dilated follicles. We view DDD as part of a spectrum of disorders which are morphologically related but vary in location and time of expression. In addition, both the clinical and histological differential diagnostic considerations are extensive.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Kim YC, Davis MD, Schanbacher CF, Su WP: Dowling-Degos disease (reticulate pigmented anomaly of the flexures): a clinical and histopathologic study of 6 cases. J Am Acad Dermatol 1999;40:462–467.
  2. Behdjet H: Acanthosis nigricans unassociated with malignancy. Bull Soc Fr Dermatol Syphiligr 1932;39:192.
  3. Dowling GB, Freudenthal W: Acanthosis nigricans. Br J Dermatol 1938;50:1147–1150.
  4. Degos R, Ossipowski B: Dermatose pigmentaire réticulée des plis. Ann Dermatol Syphiligr (Paris) 1954;81:147–151.
  5. Smith EL, Dowling GB, Wilson-Jones E: Acquired axillary and inguinal pigmentation: an epidermal naevoid abnormality not to be confused with acanthosis nigricans. Br J Dermatol 1971;85:295–296.
  6. Jones EW, Grice K: Reticulate pigmented anomaly of the flexures: Dowling Degos disease, a new genodermatosis. Arch Dermatol 1978;114:1150–1157.
  7. Betz RC, Planko L, Eigelshoven S, Hanneken S, Pasternack SM, Bussow H, Van Den Bogaert K, Wenzel J, Braun-Falco M, Rutten A, Rogers MA, Ruzicka T, Nöthen MM, Magin TM, Kruse R: Loss-of-function mutations in the keratin 5 gene lead to Dowling-Degos disease. Am J Hum Genet 2006;78:510–519.
  8. Planko L, Böhse K, Höhfeld J, Betz RC, Hanneken S, Eigelshoven S, Kruse R, Nöthen MM, Magin TM: Identification of a keratin-associated protein with a putative role in vesicle transport. Eur J Cell Biol 2007;86:827–839.
  9. Lugassy J, Itin P, Ishida-Yamamoto A, Holland K, Huson S, Geiger D, Hennies HC, Indelman M, Bercovich D, Uitto J, Bergman R, McGrath JA, Richard G, Sprecher E: Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14. Am J Hum Genet 2006;79:724–730.
  10. Wu YH, Lin YC: Generalized Dowling-Degos disease. J Am Acad Dermatol 2007;57:327–334.
  11. Bardach H, Gebhart W, Luger T: Genodermatosis in a pair of brothers: Dowling-Degos, Grover, Darier, Hailey-Hailey or Galli-Galli disease? Hautarzt 1982;33:378–383.
  12. Braun-Falco M, Volgger W, Borelli S, Ring J, Disch R: Galli-Galli disease: an unrecognized entity or an acantholytic variant of Dowling-Degos disease? J Am Acad Dermatol 2001;45:760–763.
  13. Sprecher E, Indelman M, Khamaysi Z, Lugassy J, Petronius D, Bergman R: Galli-Galli disease is an acantholytic variant of Dowling-Degos disease. Br J Dermatol 2007;156:572–574.
  14. Jacyk W, Miklaszewska M: Acquired axillary and inguinal pigmentations. Dermatologica 1973;146:262–265.
  15. Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW: Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 1995;11:462–464.
  16. El Shabrawi-Caelen L, Rütten A, Kerl H: The expanding spectrum of Galli-Galli disease. J Am Acad Dermatol 2007;56:86–91.

    External Resources

  17. Rebora A, Crovato F: The spectrum of Dowling-Degos disease. Br J Dermatol 1984;110:627–630.
  18. Müller CS, Pföhler C, Tilgen W: Changing a concept – controversy on the confusing spectrum of the reticulate pigmented disorders of the skin. J Cutan Pathol 2009;36:44–48.
  19. Liu Q, Jiang L, Liu WL, Kang XJ, Ao Y, Sun M, Luo Y, Song Y, Lo WH, Zhang X: Two novel mutations and evidence for haploinsufficiency of the ADAR gene in dyschromatosis symmetrica hereditaria. Br J Dermatol 2006;154:636–642.
  20. Davis MD, Weenig RH, Camilleri MJ: Confluent and reticulate papillomatosis (Gougerot-Carteaud syndrome): a minocycline-responsive dermatosis without evidence for yeast in pathogenesis. A study of 39 patients and a proposal of diagnostic criteria. Br J Dermatol 2006;154:287–293.
  21. Blumenthal GM, Dennis PA: PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008;16:1289–1300.
  22. Korting GW: Histologic iconography. Lentiginosis profusa perigenito-axillaris. Z Haut Geschlechtskr 1967;42:19–22.
  23. Mowad CM, Shrager J, Elenitsas R: Oral pigmentation representing Laugier-Hunziker syndrome. Cutis 1997;60:37–39.
  24. Crowe FW: Axillary freckling as a diagnostic aid in neurofibromatosis. Ann Intern Med 1964;61:1142–1143.
  25. Amer M, Mostafa FF, Nasr AN: Lentiginous macules and patches of neurofibromatosis (an approach to better terminology). J Eur Acad Dermatol Venereol 2001;15:39–42.
  26. Piñol Aguadé J, Fernández N: Enfermedad de los puntos pardos: dark dot disease. Med Cutan Ibero Lat Am 1973;7:257–262.
  27. Uttam J, Hutton E, Coulombe PA, Anton-Lamprecht I, Yu QC, Gedde-Dahl T Jr, Fine JD, Fuchs E: The genetic basis of epidermolysis bullosa simplex with mottled pigmentation. Proc Natl Acad Sci USA 1996;93:9079–9084.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50